{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"End of Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"At treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)","id":"OG000","title":"Phase II: VR-DA-EPOCH"},{"description":"Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat","id":"OG001","title":"Phase II: DA-R-EPOCH"}],"paramType":"MEDIAN","populationDescription":"Outcome measure is the difference between the baseline and specific time points (End of Cycle 2, Treatment discontinuation, 6-month, and 12-month follow-ups.\n\nOnly a few differences can be calculated.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Changes in Human Herpes Virus (HHV)-8 Viral Load","type":"SECONDARY","unitOfMeasure":"copies per 100uL"}